FDA’s Rx/Dx Co-Development Approach Overlooks Incentives – Novartis Exec
Executive Summary
FDA's concept paper on drug-diagnostic co-development does not account for "practical" issues facing firms, such as incentives, Novartis Oncology Diagnostic Development Director Mark Braganza said